Cell panel screening assays are an essential part of the drug discovery toolbox. However, fully resolving the drug response profiles of slow-acting therapeutics remains challenging with conventional short term assay formats. Elucidation of the effects of these drug candidates, and those that target epigenetic pathways, requires much greater optimization of longer-term assay conditions.
28 result(s)
In this blog, we will look at what to do once your gene editing experiment is finished and the different ways you will be able to characterize the successfully modified cell lines.
A proof-of-concept study where CRISPR-Cas9 reagents and guides to 3 genes were added to the same cell population and then a representative subset of clonal cell lines were analyzed for multiplexed gene editing efficiency.
A discussion of novel methodology and research in primary human monocytes recently published by the labs of Dr. Alex Marson and Dr. Nevan Krogan.
Detecting proteins with confidence starts with antibody validation. Here, we've outlined the key points.
Review of publications using HAP1 cells to set up validation assays beyond the typical western blot.
Our top 5 tips for working with HAP1 cells.
Here we discuss a recent paper by Gisela Jimenez-Duran and colleagues highlighting how a whole genome CRISPR knockout screen, carried out by Horizon Discovery, has enabled identification of a pre-existing inhibitor that can regulate pro-inflammatory macrophages.
Demonstration of a repeatable pooled lentiviral sgRNA screen in primary human T cells
Read about the top 4 considerations when deciding between clones and pools